Literature DB >> 23749818

An unusual presentation of MEN2A.

R Casey1, M Bell, M Keane, A Smyth.   

Abstract

A 35-year-old woman presented with non-specific symptoms of fatigue and weight loss. Radiological investigations diagnosed a metastatic process and large bilateral adrenal masses. Histology from a liver biopsy and skin biopsy confirmed a diagnosis of metastatic medullary thyroid cancer. Further biochemical investigations revealed a positive 24-h urinary metanephrine collection and evidence of primary hyperparathyroidism. Genetic testing confirmed a mutant RET oncogene, confirming our clinical suspicion of multiple endocrine neoplasia type 2 (MEN2A) syndrome. The patient had no family history of endocrine disease and presented with widespread metastatic disease, making this an unusual presentation of MEN2A syndrome. Furthermore cutaneous metastases are rarely encountered in conjunction with metastatic medullary thyroid cancer. This case draws attention to the importance of genetic counselling in first-degree relatives of patients with confirmed MEN2A. This allows for timely diagnosis and reduced morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23749818      PMCID: PMC3703066          DOI: 10.1136/bcr-2012-007171

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.

Authors:  Linwah Yip; Gilbert J Cote; Suzanne E Shapiro; Gregory D Ayers; Cynthia E Herzog; Rena V Sellin; Steven I Sherman; Robert F Gagel; Jeffrey E Lee; Douglas B Evans
Journal:  Arch Surg       Date:  2003-04

Review 2.  Thyroid cancer: a lethal endocrine neoplasm.

Authors:  J Robbins; M J Merino; J D Boice; E Ron; K B Ain; H R Alexander; J A Norton; J Reynolds
Journal:  Ann Intern Med       Date:  1991-07-15       Impact factor: 25.391

Review 3.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

Review 4.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

5.  Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid.

Authors:  M F Saad; H A Fritsche; N A Samaan
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

6.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.

Authors:  M Santoro; F Carlomagno; A Romano; D P Bottaro; N A Dathan; M Grieco; A Fusco; G Vecchio; B Matoskova; M H Kraus
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

7.  Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A.

Authors:  C J Lips; R M Landsvater; J W Höppener; R A Geerdink; G Blijham; J M van Veen; A P van Gils; M J de Wit; R A Zewald; M J Berends
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

8.  RET mutations in exons 13 and 14 of FMTC patients.

Authors:  A Bolino; I Schuffenecker; Y Luo; M Seri; M Silengo; T Tocco; G Chabrier; C Houdent; A Murat; M Schlumberger
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

Review 9.  Multiple endocrine neoplasia type 2.

Authors:  Francesca Marini; Alberto Falchetti; Francesca Del Monte; Silvia Carbonell Sala; Isabella Tognarini; Ettore Luzi; Maria Luisa Brandi
Journal:  Orphanet J Rare Dis       Date:  2006-11-14       Impact factor: 4.123

Review 10.  Multiple endocrine neoplasia type 2.

Authors:  Michael E Gertner; Electron Kebebew
Journal:  Curr Treat Options Oncol       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.